S
Sae-Won Han
Researcher at Seoul National University Hospital
Publications - 278
Citations - 8689
Sae-Won Han is an academic researcher from Seoul National University Hospital. The author has contributed to research in topics: Cancer & Breast cancer. The author has an hindex of 46, co-authored 258 publications receiving 7427 citations. Previous affiliations of Sae-Won Han include University of California, San Francisco & Seoul National University.
Papers
More filters
Journal ArticleDOI
Predictive and Prognostic Impact of Epidermal Growth Factor Receptor Mutation in Non–Small-Cell Lung Cancer Patients Treated With Gefitinib
Sae-Won Han,Tae-You Kim,Pil Gyu Hwang,Soohyun Jeong,Jeongmi Kim,In Sil Choi,Do Youn Oh,Jee Hyun Kim,Dong Wan Kim,Doo Hyun Chung,Seock-Ah Im,Young Tae Kim,Jong-Seok Lee,Dae Seog Heo,Yung-Jue Bang,Noe Kyeong Kim +15 more
TL;DR: P-Akt overexpression was associated with prolonged TTP in patients with EGFR mutation, which further support the importance of EGFR mutations with regard to gefitinib sensitivity.
Journal ArticleDOI
Optimization of Patient Selection for Gefitinib in Non–Small Cell Lung Cancer by Combined Analysis of Epidermal Growth Factor Receptor Mutation, K-ras Mutation, and Akt Phosphorylation
Sae-Won Han,Tae-You Kim,Yoon Kyung Jeon,Pil Gyu Hwang,Seock-Ah Im,Kyung-Hun Lee,Jee Hyun Kim,Dong Wan Kim,Dae Seog Heo,Noe Kyeong Kim,Doo Hyun Chung,Yung-Jue Bang +11 more
TL;DR: In addition to EGFR mutation, K-ras mutation and Akt phosphorylation aid in better prediction of gefitinib responsiveness in non–small-cell lung cancer.
Journal ArticleDOI
Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis.
Bhumsuk Keam,Seock-Ah Im,Kyung-Hun Lee,Sae-Won Han,Do-Youn Oh,Jee Hyun Kim,Se-Hoon Lee,Wonshik Han,Dong Wan Kim,Tae-You Kim,In Ae Park,Dong-Young Noh,Dae Seog Heo,Yung-Jue Bang +13 more
TL;DR: TNBC with high Ki-67 was associated with a more aggressive clinical feature despite a higher pCR rate, and high proliferation index Ki- 67 can be used for further classification of TNBC into two subtypes with different responses and prognosis.
Journal ArticleDOI
Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma
Bert H. O'Neil,John M. Wallmark,David Lorente,Elena Elez,Judith Raimbourg,Carlos Gomez-Roca,Samuel Ejadi,Sarina Anne Piha-Paul,Mark N. Stein,Albiruni Ryan Abdul Razak,Katia Dotti,Armando Santoro,Roger B. Cohen,M. Gould,Sanatan Saraf,Karen Stein,Sae-Won Han +16 more
TL;DR: Pembrolizumab demonstrated a favorable safety profile in advanced PD-L1–positive CRC, and antitumor activity was observed in a single patient with MSI-high CRC, warranting further evaluation in this patient population.
Journal ArticleDOI
Skeletal Muscle Depletion Predicts the Prognosis of Patients with Advanced Pancreatic Cancer Undergoing Palliative Chemotherapy, Independent of Body Mass Index.
Younak Choi,Do-Youn Oh,Tae Yong Kim,Kyung-Hun Lee,Sae-Won Han,Seock-Ah Im,Tae-You Kim,Yung-Jue Bang +7 more
TL;DR: Sarcopenia at diagnosis and depletion of skeletal muscle, independent of BMI change, during chemotherapy were poor prognostic factors in advanced pancreatic cancer.